RX For Africa, inc. (RXAF)

 

Company: RX For Africa, inc. (RXAF)

Website: http://www.rxforafrica.com

I would like everyone to start researching RXAF immediately! RXAF is a company everyone should add to their radar before it starts to take off in the very near future. RXAF is targeting a market that is in serious need of help and RXAF has the solution.

I'm sure everyone has read somewhere how bad and heavily affected Africa is getting with HIV/AIDS and Tubercolosis (TB) every year. This has become an epidemic in these regions as an estimated 22 million people had HIV in 2007 and approximately 1.9 million additional people were infected with HIV during that year! It has drastically gotten worse over the past two years. More than 11 million children have been orphaned by AIDS. What's crazy is that Africa accounted for 85% of the estimated global HIV positive Tuberculosis (TB) cases! Though South Africa represents 0.7% of the world's population! Globally, one person dies of TB every 20 seconds! In Africa, TB is the leading killer of people living with HIV/AIDS.

Individuals infected with TB/HIV in Africa have to navigate weak health systems and jump through numerous hurdles in order to get care. Also, most pharmaceuticals marketed in Africa are imported.

RXAF is tackling this huge problem and sees a tremendous market share opportunity that could potentially make early investors big profits. RXAF was formed in 2007 to invest in companies manufacturing generic pharmaceuticals in Sub-Saharan Africa. RXAF believes the time is right for in-country facilities that conform to good manufacturing practice and believe these companies can be run profitability while benefiting the local economies by creating jobs at all levels.

RXAF, through its wholly owned subsidiary Rx for Africa ( Ethiopia ) PLC, operates a pharmaceutical plant, formerly known as Sunshine Pharmaceutical. The plant is built on twenty three thousand square meters of land located south of Addis Ababa , Ethiopia . The plant was established to manufacture HIV/AIDS, Malaria, Tuberculosis and other generic drugs in Ethiopia . The plant currently has 6 products and within six months expects to produce a minimum of 30 new products!

I believe RXAF could become a major player in this niche market and could become one of the biggest pharmaceutical companies in Africa.

Just this morning, RXAF announced huge news of a signing of a letter of intent for a strategic alliance with Rusan Pharma, Ltd., of Mumbai , India . The alliance commences immediately, with Rusan providing Rx for Africa Inc. the tuberculosis (TB) drug, "RUCOX-4" (four drug combination) as per the recommended dosage form of the World Health Organization (WHO), which is also approved by the Ethiopian Ministry of Health and already marketed in some CIS & African countries! Per capita the highest number of deaths and the highest mortality from TB in the world are in Sub-Saharan Africa. "Tuberculosis is a huge problem in our region," said Dr. Mulugetta Bezzabeh, CEO of Rx for Africa , "and RUCOX-4 is an important addition to our product line. We expect significant revenue and profit to be derived from marketing it."

In addition, the agreement also maps out a strategy in which Rx Africa ( Ethiopia ) PLC will market Rusan Pharma's 202 drugs in Ethiopia , and other sub-Saharan African countries. Importantly, Rusan will assist Rx in developing anti-malarials and HIV medications for these markets, and will assist us to start manufacturing their whole list of drugs in our Ethiopian facilities. Dr. Navin Saxena, Chairman of Rusan Pharma, Ltd. commented, "Rusan is pleased to enter into strategic alliance with Rx for Africa . Ethiopia is a big market with significant potential for growth in the area of Tuberculosis, HIV AIDS & Malaria products. Rusan has the capability to develop various drug delivery systems besides the conventional dosage forms and will use its expertise to bring these to the market in short time."

Here's a link to the PR-

http://finance.yahoo.com/news/Rx-for-Africa-Inc-Signs-prnews-15463117.html?.v=1

Also, I have always stated to you how important strong experienced management is and RXAF added a top biotech executive, Mr. William Pursley, as Chairman of RXAF!

For 25 years Mr. Pursley has held major executive positions in the biotech industry. In 1985 he joined Genentech, Inc., and was on the marketing team that launched Human Growth Hormone (HGH), one of biotech's first products. It was a huge success. In 1985 Pursley joined Genzyme Corp as VP of Marketing and spearheaded the launch of Ceradase, an Orphan Drug for the treatment of Gaucher's Disease. Only 3,000 people in the US suffer from Gaucher's. Hopes were that the drug would reach $40 million in sales by the third year on the market. It did $120 million in year three. Ceradase has gone on to be Genzyme's biggest seller. It's sales currently exceed $600 million. Genzyme's market cap exceeds $18 billion. Mr. Pursley subsequently became CEO of Osiris Therapeutics, Inc., a leading mesenchymal stem cell company, which recently announced a major corporate alliance with Genzyme.

In 1999, Mr. Pursley joined Transkaryotic Therapeutics as Senior VP of Operations, supervising the European launch of the company's first product, Replagal, an orphan drug for Fabry's disease. The drug took 75% market share in Europe . In 2005, Transkaryotic was sold to Shire Pharmaceuticals for $1.6 billion. He has also achieved great success with reimbursement programs for the drugs he has marketed. "With Ceradase, we were successful in getting insurance companies to reimburse patients up to $350,000 a year for their treatment. Today, in Africa, there are multi-billion dollar funds such as PEPFAR and The Global Fund set up to reimburse companies who distribute drugs for disease such as HIV and malaria. I believe I can help Rx access these funds."

As you can see RXAF almost has everything in place to become a leading pharmaceutical company in Africa. I can't believe it is trading under $0.10!

Wall Street Grand will be following RXAF for the long-term and looks forward to a promising future with this company. I believe RXAF could become one of our biggest winners of all time! RXAF was brought to my attention from one of histories most successful biotech investors in the world!

Start to research RXAF right now! We will have more on RXAF in the future!

If you have any questions or comments please give us a call during market hours at    1-888-925-8247. Don't forget to help spread the word!

MORE UPDATES TO COME...

 

If you have any questions feel free to email me or call us at

1-888-9-Club Grand -or- staff@wallstreetgrand.com